MedDay is committed to developing new treatments for nervous system disorders.

    Clinical Trials

    Please note our product candidates are not yet available or approved for use.

    MedDay is developing products in a tightly regulated environment of clinical studies that are reviewed and approved by the national respective authorities to establish a maximum safety level for patients. Currently, therefore, access to our trials is limited to patients meeting the eligibility criteria of our clinical trials.

    MS-SPI and MS-ON Trial Results

    MedDay reported full study results from the Phase IIb/III MS-SPI and MS-ON trials, including the MS-SPI extension data, at the American Academy of Neurology Annual Meeting (AAN) in April 2016.

    MS-SPI and MS-ON studies tested the efficacy of lead product candidate MD1003, a patented pharmaceutical-grade biotin administered at a dose of 300 mg per day in the treatment of multiple sclerosis (MS) and particularly of the most difficult to treat “not-active progressive MS,” for which there is no approved drug.

    Overall these data show the best effect size ever observed to date and confirm the good safety profile of MD1003.

    For more information on the study results, please click here

    Ongoing Trials:

    Lead product candidate MD1003 is currently being evaluated in the following clinical trials:

    Indication

    Study code

    EudraCT No

    Progressive MS:

    MS-ON study

    2013-002112-27

     

    MS-SPI study

    2013-002113-35

     

    SPI2 study

    2016-000700-29

    Adrenomyeloneuropathy

    MD1003-AMN study

    2014-000698-38

     

    MedDay is also currently running pilot studies with MD1003 in other indications.

    Upcoming Trials:

    MD1103 – Autism Spectrum Disorders

    MD1105 – Alzheimer’s Disease

    Request for Medical Information:

    If you are a health care professional and would like information about becoming an investigator for one of MedDay’s clinical trials, please contact medinfo@medday-pharma.com

    If you are a health care professional and would like to request details about MedDay’s Named Patient Use Programme (available in some countries), please contact NPU@medday-pharma.com

    MedDay SA au capital de 116 660 €
    Siège social : 96 Boulevard Haussmann 75008 Paris
    RCS PARIS 534 957 865
    Publication Director : Dr Frédéric Sedel